- Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme ( NASDAQ: EPZM ) to Aug. 11, from Aug. 8.
- The French drugmaker noted that the decision was taken to allow additional time for expiration or termination of waiting period under U.S. antitrust law.
- As of Aug. 4, ~42.26M shares, representing ~25% of outstanding shares, were validly tendered.
- According to Ipsen, more than 50% of shares needs to be tendered for the tender offer to be completed, among other conditions.
- In June, Ipsen said it was acquiring Epizyme for $247M plus contingent value right (CVR), following which an all-cash tender offer was begun to acquire all outstanding shares of Epizyme ( EPZM ) at $1.45/share plus a CVR of $1 per share.
For further details see:
Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance, required shares